Skip to main content

Table 4 Correlations between measures of current psychopathology, disease course and AAP use in schizophrenia patients

From: Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case–control study

  ADMA L-arginine:ADMA ratio
PANSS score 0.16 (−0.16 to 0.45) p = 0.31 0.13 (−0.19 to 0.42) p = 0.44
Duration of disease −0.04 (−0.34 to 0.28) p = 0.82 0.29 (−0.02 to 0.55) p = 0.07
Lifetime admissions −0.06 (−0.37 to 0.25) p = 0.70 0.32 (0.00 to 0.57) p = 0.05
Defined Daily Dose of AAP 0.17 (−0.15 to 0.46) p = 0.30) 0.004 (−0.31 to 0.32) p = 0.98
Duration of AAP treatment 0.14 (−0.18 to 0.43) p = 0.40 −0.16 (−0.45 to 0.16) p = 0.32
  1. Data are presented as Spearman correlation coefficients (ρ) with 95-% confidence limits (Fisher’s z-transformation with normal approximation) and corresponding p-values. Abbreviations:ADMA Asymmetric dimethyl arginine, PANSS Positive and Negative Syndrome Scale, AAP Atypical antipsychotics.